Be­yond BR­CA: As­traZeneca rounds out ES­MO with a case for ex­pand­ed bio­mark­er in prostate can­cer

BARCELONA — When it comes to se­lect­ing pa­tients for PARP in­hibitors, mu­ta­tions in the BR­CA1 and BR­CA2 genes have been the go-to bio­mark­er, the surest way of find­ing those most like­ly to ben­e­fit from the ther­a­py. But As­traZeneca and Mer­ck are mak­ing some head­way in carv­ing out a new niche for it­self in prostate can­cer.

Greg Rossi

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER